In July, Solve hosted a webinar featuring representatives of the ADDRESS-LC Trial, which was designed to assess the potential impact of the drug bezisterim on cognitive impairment/brain fog and fatigue in people with Long Covid.
The lived experience of patients has informed the development and conduct of the ADDRESS-LC trial, and patient-researcher collaboration has been a crucial component. Now, in response to input from scientific and patient communities, BioVie is opening the trial up to all qualified individuals, including those who have been suffering from Long Covid since 2020.
Additionally, new sites have begun enrolling. Visit the trial website for more information on site locations and other trial requirements.
Patient representative Ezra Spier noted, “I’ve been sick with Long Covid for three years. When I joined the ADDRESS-LC trial team as a patient representative, study participation was limited to those with Long Covid for two years or less. It was disappointing to learn I didn’t qualify for this important trial, but I understood the reason for the two-year restriction based upon what was known about Long Covid when the trial was being designed. I’m thrilled that Biovie continued to track new research findings for Long Covid, and now more of us can join the ADDRESS-LC Trial and help find a treatment for the brain fog, cognitive impairment, and fatigue that affect us every day.”
Learn more about the trial at www.addresslc.com and watch Solve’s ADDRESS-LC Trial webinar here.